Back to User profile » Dr Derek Skinner
Papers published by Dr Derek Skinner:
Development and Internal Validation of a Prediction Model for Major Cardiovascular and Respiratory Events in Chronic Obstructive Pulmonary Disease: Nationwide Primary Care Electronic Medical Records Cohort Study
Gale CP, Bhutani M, Chan JSK, Townend J, Patel MS, Sadatsafavi M, Henley W, Ariti C, Carter V, Couper A, Hubbard R, Kocks JWH, Pullen R, Skinner D, Price D
Pragmatic and Observational Research 2026, 17:551291
Published Date: 10 March 2026
The Potential Impact of GLP-1 Receptor Agonists on Exacerbation Risk in Patients with COPD and Type 2 Diabetes: A Real-World Population-Based Observational Study
Alcázar-Navarrete B, Heatley H, Kaplan A, Tan LT, Koh MS, Sattar N, Townend J, Skinner D, Carter V, Price D
Pragmatic and Observational Research 2026, 17:550543
Published Date: 30 January 2026
Budesonide/Glycopyrrolate/Formoterol for the Management of COPD in a UK Primary Care Population: Real-World Use and Early Medication Success
Müllerová H, Chan JSK, Heatley H, Carter V, Townend J, Skinner D, Franzén S, Marshall J, Price D
International Journal of Chronic Obstructive Pulmonary Disease 2024, 19:1153-1166
Published Date: 24 May 2024
Risk of Pneumonia in Patients with COPD Initiating Fixed Dose Inhaled Corticosteroid (ICS) / Long-Acting Bronchodilator (LABD) Formulations Containing Extrafine Beclometasone Dipropionate versus Patients Initiating LABD Without ICS
Price D, Henley W, Cançado JED, Fabbri LM, Kerstjens HA, Papi A, Roche N, Şen E, Singh D, Vogelmeier CF, Nudo E, Carter V, Skinner D, Vella R, Soriano JB, Kots M, Georges G
Pragmatic and Observational Research 2024, 15:1-16
Published Date: 20 January 2024
A Long-Term Study of Adverse Outcomes Associated With Oral Corticosteroid Use in COPD
Tse G, Emmanuel B, Ariti C, Bafadhel M, Papi A, Carter V, Zhou J, Skinner D, Xu X, Müllerová H, Price D
International Journal of Chronic Obstructive Pulmonary Disease 2023, 18:2565-2580
Published Date: 15 November 2023
Interclass Difference in Pneumonia Risk in COPD Patients Initiating Fixed Dose Inhaled Treatment Containing Extrafine Particle Beclometasone versus Fine Particle Fluticasone [Corrigendum]
Price DB, Henley W, Cançado JED, Fabbri LM, Kerstjens HA, Papi A, Roche N, Şen E, Singh D, Vogelmeier CF, Barille S, Nudo E, Carter V, Skinner D, Vella R, Georges G
International Journal of Chronic Obstructive Pulmonary Disease 2022, 17:489-490
Published Date: 7 March 2022
Interclass Difference in Pneumonia Risk in COPD Patients Initiating Fixed Dose Inhaled Treatment Containing Extrafine Particle Beclometasone versus Fine Particle Fluticasone
Price DB, Henley W, Cançado JED, Fabbri LM, Kerstjens HA, Papi A, Roche N, Şen E, Singh D, Vogelmeier CF, Barille S, Nudo E, Carter V, Skinner D, Vella R, Georges G
International Journal of Chronic Obstructive Pulmonary Disease 2022, 17:355-370
Published Date: 15 February 2022
Management Of Community-Acquired Pneumonia: An Observational Study In UK Primary Care
Launders N, Ryan D, Winchester CC, Skinner D, Konduru PR, Price DB
Pragmatic and Observational Research 2019, 10:53-65
Published Date: 23 September 2019
Real-life treatment of rhinitis in Australia: a historical cohort study of prescription and over-the-counter therapies for patients with and without additional respiratory disease
Price DB, Smith PK, Harvey RJ, Carney AS, Kritikos V, Bosnic-Anticevich SZ, Christian L, Skinner D, Carter V, Durieux AMS
Pragmatic and Observational Research 2018, 9:43-54
Published Date: 15 August 2018